A polymorphism at codon 133 of the tumor suppressor RASSF1A is associated with tumorous alteration of the breast

International Journal of Oncology

Volumn 27, Issue 1, 2005, Pages 185-191

  Schagdarsurengin, Undraga ^a   Seidel, Claudia ^a   Ulbrich, Eva J ^b   Kölbl, Heinz ^c   Dittmer, Jürgen ^b   Dammann, Reinhard ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Breast cancer; Fibroadenoma; Polymorphism; RASSF1 A

Indexed keywords

PRIMER DNA; RASSF1 PROTEIN, HUMAN; SERINE; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ALLELE; ARTICLE; BREAST; BREAST TUMOR; CHEMISTRY; CODON; COHORT ANALYSIS; DNA SEQUENCE; EXON; FEMALE; FIBROADENOMA; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; PROTEIN TERTIARY STRUCTURE; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM; TEMPERATURE;

ADULT; AGED; ALLELES; BREAST; BREAST NEOPLASMS; CODON; COHORT STUDIES; DNA PRIMERS; EXONS; FEMALE; FIBROADENOMA; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTEIN STRUCTURE, TERTIARY; SEQUENCE ANALYSIS, DNA; SERINE; TEMPERATURE; TUMOR SUPPRESSOR PROTEINS;

EID: 24644435402     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.27.1.185     Document Type: Article

References (40)

1. Hunter CP: Epidemiology, stage at diagnosis, and tumor biology of breast carcinoma in multiracial and multiethnic populations. Cancer 88: 1193-1202,2000.
2. Blackwood MA and Weber BL: BRCA1 and BRCA2: from molecular genetics to clinical medicine. J Clin Oncol 16: 1969-1977, 1998.
3. Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J and Stratton MR: Prevalence of BRCA1 and BRCA2 gene mutations in patients with earlyonset breast cancer. J Natl Cancer Inst 91: 943-949, 1999.
4. Teng DH, Bogden R, Mitchell J, Baumgard M, Bell R, Berry S, Davis T, Ha PC, Kehrer R, Jammulapati S, Chen Q, Offit K, Skolnick MH, Tavtigian SV, Jhanwar S, Swedlund B, Wong AK and Kamb A: Low incidence of BRCA2 mutations in breast carcinoma and other cancers. Nat Genet 13: 241-244, 1996.
5. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J and Miki Y: BRCA1 mutations in primary breast and ovarian carcinomas. Science 266: 120-122, 1994.
6. Miki Y, Katagiri T, Kasumi F, Yoshimoto T and Nakamura Y: Mutation analysis in the BRCA2 gene in primary breast cancers. Nat Genet 13:245-247, 1996.
7. Lancaster JM, Wooster R, Mangion J, Phelan CM, Cochran C, Gumbs C, Seal S, Barfoot R, Collins N, Bignell G, Patel S, Hamoudi R, Larsson C Wiseman RW, Berchuck A, Iglehart JD, Marks JR, Ashworth A, Stratton MR and Futreal PA: BRCA2 mutations in primary breast and ovarian cancers. Nat Genet 13: 238-240, 1996.
8. Ingvarsson S: Molecular genetics of breast cancer progression. Semin Cancer Biol 9: 277-288, 1999.
9. Weber BL: Update on breast cancer susceptibility genes. Recent Results Cancer Res 152: 49-59, 1998.
10. Sekido Y, Ahmadian M, Wistuba II, Latif F, Bader S, Wei MH, Dull FM, Gazdar AF, Lerman MI and Minna JD: Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene. Oncogene 16: 3151-3157,1998.
11. Dammann R, Li C, Yoon JH, Chin PL, Bates S and Pfeifer GP: Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25: 315-319,2000.
12. Dammann R, Schagdarsurengin U, Strunnikova M, Rastetter M, Seidel C, Liu L, Tommasi S and Pfeifer GP: Epigenetic inactivation of the Ras-association domain family 1 (RASSFIA) gene and its function in human carcinogenesis. Histol Histopathol 18:665-677,2003.
13. Pfeifer GP, Yoon JH, Liu L, Tommasi S, Wilczynski SP and Dammann R: Methylation of the RASSFIA gene in human cancers. Biol Chem 383: 907-914, 2002.
14. Dammann R, Yang G and Pfeifer GP: Hypermethylation of the cpG island of Ras association domain family IA (RASSFIA), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res 61: 3105-3109,2001.
15. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, Rändle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar AF, Lerman MI, Zabarovsky E, White M and Minna JD: Epigenetic inactivation of RASSFIA in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 93: 691-699, 2001.
16. Agathanggelou A, Honorio S, MacArtney DP, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw JA, Hosoe S, Lerman MI, Minna JD, Mäher ER and Latif F: Methylation associated inactivation of RASSFIA from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 20: 1509-1518,2001.
17. Fackler MJ, McVeigh M, Evron E, Garrett E, Mehrotra J, Polyak K, Sukumar S and Argani P: DNA methylation of RASSF1 A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer 107: 970-975, 2003.
18. Muller HM, Widschwendter A, Fiegl H, Ivarsson L, Goebel G, Perkmann E, Marth C and Widschwendter M: DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res 63: 7641-7645, 2003.
19. Lehmann U, Langer F, Feist H, Glockner S, Hasemeier B and Kreipe H: Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol 160: 605-612, 2002.
20. Dreijerink K, Braga E, Kuzmin I, Geil L, Duh FM, Angeloni D, Zbar B, Lerman MI, Stanbridge EJ, Minna JD, Protopopov A, Li J, Kashuba V, Klein G and Zabarovsky ER: The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sei USA 98: 7504-7509, 2001.
21. Khokhlatchev A, Rabizadeh S, Xavier R, Nedwidek M, Chen T, Zhang XF, Seed B and Avruch J: Identification of a novel Ras-regulated proapoptotic pathway. Curr Biol 12: 253-265, 2002.
22. Ortiz-Vega S, Khokhlatchev A, Nedwidek M, Zhang XF, Dammann R, Pfeifer GP and Avruch J: The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Norel. Oncogene 21: 1381-1390, 2002.
23. Vos MD, Ellis CA, Bell A, Birrer MJ and Clark GJ: Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J Biol Chem 275: 35669-35672, 2000.
24. Van Engeland M, Roemen GM, Brink M, Pachen MM, Weijenberg MP, De Bruine AP, Arends JW, van den Brandt PA, De Goeij AF and Herman JG: K-ras mutations and RASSF1A promoter methylation in colorectal cancer. Oncogene 21; 3792-3795, 2002.
25. Dammann R, Schagdarsurengin U, Liu L, Otto N, Gimm O, Dralle H, Boehm BO, Pfeifer GP and Hoang-Vu C: Frequent RASSFIA promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene 22: 3806-3812, 2003.
26. Liu L, Tommasi S, Lee DH, Dammann R and Pfeifer GP: Control of microtubule stability by the RASSFIA tumor suppressor. Oncogene 22: 8125-8136, 2003.
27. Vos MD, Martinez A, Elam C, Dallol A, Taylor BJ, Latif F and Clark GJ: A role for the RASSFIA tumor suppressor in the regulation of tubulin polymerization and genomic stability. Cancer Res 64: 4244-4250, 2004.
28. Dallol A, Agathanggelou A, Fenton SL, Ahmed-Choudhury J, Hesson L, Vos MD, Clark GJ, Downward J, Mäher ER and Latif F: RASSFIA interacts with microtubule-associated proteins and modulates microtubule dynamics. Cancer Res 64: 4112-4116, 2004.
29. Song MS, Song SJ. Ayad NG, Chang JS, Lee JH, Hong HK, Lee H, Choi N, Kim J, Kim H, Kim JW, Choi EJ, Kirschner MW and Lim DS: The tumour suppressor RASSFIA regulates mitosis by inhibiting the APC-Cdc20 complex. Nat Cell Biol 6: 129-137,2004.
30. Shivakumar L, Minna J, Sakamaki T, Pestell R and White MA: The RASSFIA tumor suppressor blocks cell cycle progression and inhibits cyclin Dl accumulation. Mol Cell Biol 22: 4309-4318, 2002.
31. Tommasi S, Dammann R, Zhang Z, Wang Y, Liu L, Tsark WM, Wilczynski SP, Li J, You M and Pfeifer GP: Tumor susceptibilty of Rassf la knockout mice. Cancer Res 65: 92-98, 2005.
32. Lo KW, Kwong J, Hui AB, Chan SY, To KF, Chan AS, Chow LS, Teo PM, Johnson PJ and Huang DP: High frequency of promoter hypermethylation of RASSFIA in nasopharyngeal carcinoma. Cancer Res 61: 3877-3881, 2001.
33. Fitzgibbons PL, Henson DE and Hutter RV: Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists. Arch Pathol Lab Med 122: 1053-1055, 1998.
34. Oluwole SF and Freeman HP: Analysis of benign breast lesions in blacks. Am J Surg 137: 786-789, 1979.
35. Kuzmin I, Gillespie JW, Protopopov A, Geil L, Dreijerink K, Yang Y, Vocke CD, Duh FM, Zabarovsky E, Minna JD, Rhim JS, Emmert-Buck MR, Linehan WM and Lerman MI: The RASSFIA tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res 62: 3498-3502, 2002.
36. Kim ST, Lim DS, Canman CE and Kastan MB: Substrate specificities and identification of putative substrates of ATM kinase family members. J Biol Chem 274: 37538-37543, 1999.
37. Kastan MB and Lim DS: The many substrates and functions of ATM. Nat Rev Mol Cell Biol 1: 179-186, 2000.
38. Mathe E: RASSFIA, the new guardian of mitosis. Nat Genet 36: 117-118,2004.
39. Alle KM, Henshall SM, Field AS and Sutherland RL: Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. Clin Cancer Res 4: 847-854, 1998.
40. Schagdarsurengin U, Wilkens L, Steinemann D, Flemming P, Kreipe HH, Pfeifer GP, Schlegelberger B and Dammann R: Frequent epigenetic inactivation of the RASSFIA gene in hepatocellular carcinoma. Oncogene 22: 1866-1871, 2003.